Clinical Trials Arena on MSN

OrsoBio announces clinical trial progress for TLC-2716 metabolic therapy

The placebo-controlled, double-blind, randomised Phase I trial involved 100 healthy participants.
Study Finds on MSN

First human trial shows experimental pill cuts stubborn blood fats by up to 60%

In A Nutshell The small, short trial showed no serious side effects, but much larger and longer studies are needed to prove ...

Oral drug can safely lower triglycerides and other blood lipids, clinical trial finds

When eating, the body converts extra calories, especially from carbs, sugar, fats, and alcohol, into triglycerides.
Yahoo Finance

OrsoBio to Present Phase 1 Data for the Liver-Targeted LXR Inverse Agonist TLC-2716 in Development for Severe Hypertriglyceridemia and NASH at AHA’s Scientific Sessions 2023

-- Data confirm the safety, tolerability, and lipid lowering benefits of TLC-2716 in healthy volunteers -- MENLO PARK, Calif., November 06, 2023--(BUSINESS WIRE)--OrsoBio, Inc., a clinical-stage ...
Business Wire

OrsoBio Announces Acquisition of LXR Inverse Agonist Program for Treatment of Severe Dyslipidemias from Phenex Pharmaceuticals

PALO ALTO, Calif.--(BUSINESS WIRE)--OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of assets relating ...
Business Wire

OrsoBio to Present Phase 1 and Preclinical Data for Liver-Targeted Mitochondrial Protonophore TLC-6740 at the American Diabetes Association’s 84 th Scientific Sessions

MENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new data for ...